Keywords: Conventional radiotherapy; FLASH radiotherapy; pulse radiation; tumor tissue; ultra-high dose rate radiotherapy
No tumor group can be irresponsive to chemotherapy,
especially radiotherapy, when applied in sufficient
doses. However, in most cases, it is not possible to give effective doses that can destroy the tumor due
to side effects and damage that may occur in healthy,
normal tissues. Although current technological possibilities
transmit the rays to the target area and protect
the surrounding healthy tissues and organs much
more effectively than before, there is a need for more
studies and scientific content on this subject.[
In radiation therapy, a treatment method specifically
targeted to a specific area, radiation energy neutralizes
cancer cells. Radiotherapy ionizes atoms. It is
planned to damage the DNA structures of tumor cells
to kill them. This damage occurs by breaking the double
helix structure in DNA. However, both normal and
cancerous cells in the area where the treatment is given
are affected by this situation. However, the damage sustained
by healthy normal cells is repaired much more
quickly. Cancer cells, on the other hand, are targeted at
proliferation and grow much faster. Therefore, it lags
behind healthy cells in detecting and repairing DNA
damage. There is a specific limit for healthy cells to be
exposed to radiation. In this process, attention should
be paid to the balance of the amount of radiation given
to the individual, which should be adjusted carefully.
The process of dividing the total dose to be delivered
in treatment by certain levels daily, that is, the fraction,
allows healthy cells to repair themselves.[
Side effects shown may vary from person to person.
However, it also depends on the area being treated and
the characteristics of the tumor. There are also many
factors, such as total dose, dose in each application, and
the person's sensitivity to radiation therapy. In addition,
other treatment methods the person receives, if any, may
also be effective. During the process, swelling may occur
in the tissues.[
The technique, called flash radiotherapy, where shots
are fired for up to seconds, and the dose rate is between
30 and 106 Gy/s, offers a procedure several hundred times faster than conventional radiotherapy. Scientific
studies show that the lethal effect on the mass is similar
to regular radiotherapy, but the side effects on healthy
tissues are minimal. Radiotherapy aims to destroy cancer
cells and minimize damage and any side effects to
the rest of the body.[
UNDERSTANDING TARGET PULSE RADIATION
The radiation leaves the output of linac in pulses.
The duration and energy transported in a pulse (average
dose) depends on the properties of the source of
electrons and the properties of the accelerating device
generating high-frequency (50-300) Hz. The dose absorbed
in the tissue depends on both electrons" energies
(related to their acceleration) and their quantity (number).
The clinical radiation accelerators deliver much
fewer electrons per pulse than industrial accelerators,
where much higher beam intensities are needed. The
conventional radiotherapy pulses can be sequenced
with 100 Hz (at 10 ms intervals).[
In the case of an example, the dose rate at a standard
condition in a phantom is 0.02 Gy/s (1.2 Gy/min),
then during a session of 2 min, a fraction dose of 2.4 Gy
is delivered in 12000 pulses. The dose delivered during
one pulse is 0.0002 Gy, and the dose rate within a pulse
is around 50 Gy/s. In FLASH radiotherapy, the duration
of treatment and average dose rate are assumed
to be <200 ms and bigger than 40 Gy/s. Assuming the
literature reported a pulse sequencing scheme of 100
Hz,[
Although the aforementioned innovation poses
a window of opportunity, it also escalates challenges
on accurate dose adjustment and dose-response relationship.
To obtain a dose of 8 Gy in 200 ms requires
an increase in the energy transported per time unit,
which requires strengthening the energy transported
per pulse and perhaps also by producing more pulses
per time unit (higher frequencies such as 300 vs.
50 Hz) or prolonging the pulse duration. As FLASH
technology must transport significantly more energy
within a pulse, we need sources emitting thousands
more electrons per pulse.[
ADVANTAGES OF UTILIZING PROTONS
Uveal melanoma is one of the cancers most commonly
treated with proton. Other areas of use are the
treatment of pediatric cancers, cranially located tumors
(chondroblastoma, chordoma), head-and-neck
cancers, brain and spinal cord, pelvis, para-aortic tumors
(seminoma), spine tumors, lymphomas, prostate
cancer, digestive system cancers, breast cancer, eye, and
second series irradiations.[
Although the majority of cancer types for which radiotherapy
is applied are included in the field of use of
proton therapy, primarily pediatric tumors are a priority.
To minimize secondary cancers that may occur as
a result of radiotherapy in children, the basic principle
is to keep the integral dose received by the whole body
to a minimum, and proton therapy provides this best.
The most critical success of proton therapy in pediatric
tumors is that it improves treatment-related morbidity
by delivering a significant reduction in the permanent
harmful effects that may occur due to long-term
radiotherapy in children and a reduction in the development
of secondary tumors.[
Briefly, the advantages of particle radiotherapy can
be elaborated as being more biologically effective than
photons and, therefore, may increase the chance of response
to treatment. In addition, resistant tumors that
do not respond to conventional radiotherapy can be effectively
treated. It can easily reach tumors deep in the
body. Charged particles are accelerated to more than a
quarter of the speed of light and targeted at the tumor
tissue.[
MECHANISM OF ACTION IN FLASH
RADIOTHERAPY
REACTIVE OXYGEN SPECIES-MEDIATED CELL
DAMAGE-THE OXYGEN EFFECT
The tumor cells are composed of oxic, hypoxic, and
anoxic populations, whereas normal tissues depend on
oxygen supply. One study showed that a 10 Gy radiation
dose delivered to the brain by FLASH-RT resulted
in lower primary oxygen tension in the target tissue
than in the skin, providing a neuroprotective effect.[
IMMUNE AND INFLAMMATORY RESPONSE
DOSING CHALLENGE IN FLASH
RADIOTHERAPY
VERY HIGH ENERGY ELECTRONS (VHEE)
It is important to get acquainted with the mechanism
of radiation delivery to the target in terms of time,
dose, and structural changes produced by radiation at
both the molecular and tissue levels. The commercially
available linear accelerators generate beams in pulses
at regularly specific intervals. This process differs
significantly from older radiotherapy delivery techniques
(Cobalt-90 units), which emit gamma radiation
through radioactive decay.[
The main physical property of the proton is that it is
superior to photons due to its "Bragg peak." Until the
desired depth is reached, it leaves less of its energy
than the photon in normal tissues, while at the desired
depth, that is, in the tumor tissue, it discharges all of its
remaining energy and resets. Since it releases its energy
into the tumor after this depth, there is no unnecessary
exit dose and no irradiation in normal tissues. Therefore,
the damage to healthy tissues remains minimal.
[
The main logic that lies beneath high-dose radiation
with FLASH-RT is healthy tissue protection compared to
conventional radiotherapy. The biological mechanism of
FLASH radiotherapy is not fully elucidated but is mainly
based on two hypotheses. The first one is believed to be
the "oxygen effect," which scavenges free oxygen species
and removes and decays free radicals. The second mechanism
is explained through the distinct immune and
inflammatory response compared to conventional radiotherapy,
leading to enhanced anti-tumor effects.[
The ultra-high dose radiation rates contribute to oxygen
depletion in normal tissues, thereby inducing radioresistance,
which means that healthy tissues surrounding
the target can tolerate radiation better. Evidence is
based on animal studies (Mouse model).[
The data on immune and inflammatory responses are
controversial. In animal studies, it was elaborated that
DNA damage and inflammation indicated the signaling
pathway of TGF was downregulated in mice.[
The dosing adjustment in conventional radiotherapy
depends on achieving biological response. A wellestablished
fractionation scheme exists rather than a
dose rate by clinicians. A majority of the radiotherapy techniques utilize only a few linacs, all of which generate
radiation using similar technology with similar
dose rate schemes. On the contrary, FLASH-RT requires
significant magnification of energy transfer in
a short period. Measurement accuracy is challenging
due to the time intensity of pulsed energy transport.
A precise description of the physical parameters is essential
to ensure proper induction of the FLASH effect
in biological tissue and to select the optimal pulse size
and repetition frequency of the FLASH dose.[
The use of VHEE, in the range of 50-250 MeV, can
penetrate greater depths. However, their use is limited
due to technical issues related to electron acceleration
in a conveniently sized medical device, neither too big
nor too complicated. The additional advantage is that
the dose distributions of VHEE electrons seem less
dependent on body inhomogeneities than those obtained
using protons.[
Radiotherapy is required to produce a therapeutic
dose at depths >15 cm in the body. For this reason,
electron beam FLASH-RT is unlikely to revolutionize
radiotherapy due to the simple fact that the benefits of
this technique are only applicable to skin cancers or
tumors located within a few centimeters of the body
surface. Possible solutions are photon or proton beambased
FLASH-RT or VHEE.[
Conventional radiotherapy is based on 15 MV photon
beams, which is sufficient to obtain good dose coverage
for all tumors due to the properties of the interaction
between photons and tissues. However, to get ultra-high
dose rates for photons, we must first solve technical
challenges related to the low efficiency of converting
electron beams to photon beams. Only a tiny fraction
of the energy fluence of electrons is transferred to photons,
with most of the energy dissipated through various phenomena, including heat. This means that a FLASH
photon accelerator must have a source capable of producing
many more electrons (by a factor of 1000) than is
achievable with currently available devices, and further
on, the problems with the acceleration of such quantity
of electrons and their energy transfer to photons have to
be solved.[
Bourhis et al.[
FLASH-RT may be indicated in two main clinical
scenarios: (i) The treatment of radioresistant tumors
and (ii) the minimization of radiation-induced toxicity
when the high doses needed for local control would result
in unacceptable toxicity if delivered with conventional
radiotherapy. In the first scenario, dose escalation
could be achieved without inducing additional radiation-
related side effects, potentially improving the therapeutic
index. In the second scenario, FLASH-RT could
reduce treatment-related toxicity while still earning a
reasonable degree of local control. This potential benefit
of FLASH-RT is essential given that many patients are
not candidates for radiotherapy because they cannot tolerate
the high doses needed for local disease control. In
this regard, it is worth noting that it may be possible to
generate the FLASH effect at lower doses, which would
further expand the clinical potential of FLASH-RT;
however, more research is needed in this area.[
Last but not least, another factor that must be considered
in FLASH-RT is the biological diversity in
most cancers. Given that all effects occur on a cellular
level, tumors of different origins located in different
environments may respond differently to the dose
rate used in FLASH-RT.[
Peer-review: Externally peer-reviewed.
Conflict of Interest: I have no conflict of interest.
Financial Support: None declared.